SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

HIV infected subjects receiving antiretroviral treatment for greater than 6 years with be evaluated for clinical lipoatrophy and mitochondrial function after switching nucleoside analogues from stavudine (d4T) to tenofovir treatment and after 4.

Hypothesis: Tenofovir therapy will increase peripheral fat content as assessed by DEXA and mitochondrial function at 48 weeks.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Northwestern University
• Collaborator: Abbott

Criteria

Inclusion Criteria:

• HIV infection

• Receiving Kaletra, stavudine, and lamivudine for greater than 6 years (through Abbott M97-720 study)

• Planning to switch from stavudine to tenofovir

Exclusion Criteria:

• Will continue to receive stavudine